""

Hepatobiliary tumors

Recruiting after consultation
Open recruiting

Neoadjuvant Therapy

There are currently no studies available

Adjuvant Therapy

Title: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)
Phase: III
Contact: Margit Peters-Hornig / (Kontaktperson)
Email-Address: Margit.Peters-Hornig@med.uni-heidelberg.de
Clinical Investigator: Prof. Dr.Dr.Christoph Springfeld
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT02170090
EudraCT-Number: siehe EU klinisches Studienregister 2012-005078-70

Surgical Study

There are currently no studies available

Radiotherapy Study

Title: Phase I study evaluating the treatment of patients with advanced hepatocellular carcinoma (HCC) with Carbon Ion Radiotherapy
Phase: I
Contact: Karen Lossner / (Kontaktperson)
Email-Address: karen.lossner@med.uni-heidelberg.de
Clinical Investigator: Prof. Dr.Dr.rer.nat. Jürgen Debus
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT01167374
EudraCT-Number: siehe EU klinisches Studienregister 2010-018328-23

Metastatic Disease: First-Line-Therapy

Title: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Phase: III
Contact: Margit Peters-Hornig / (Kontaktperson)
Email-Address: Margit.Peters-Hornig@med.uni-heidelberg.de
Clinical Investigator: Prof. Dr. Karl-Heinz Weiss
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03773302
EudraCT-Number: siehe EU klinisches Studienregister 2018-004004-19
Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Phase: II
Contact: Elisabeth Lawrence / (Study Nurse)
Email-Address: Elisabeth.Lawrence@med.uni-heidelberg.de
Clinical Investigator: Prof. Dr.Dr.Christoph Springfeld
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT02568267
EudraCT-Number: siehe EU klinisches Studienregister 2015-003385-84

Metastatic Disease: Follow-Up Care

There are currently no studies available

Others

There are currently no studies available